Augmentin Es-600

Urinary Tract Infections, Sinusitis, Gonorrhea + 11 more

Treatment

2 FDA approvals

20 Active Studies for Augmentin Es-600

Treatment for

Urinary Tract Infections

What is Augmentin Es-600

Amoxicillin

The Generic name of this drug

Treatment Summary

Amoxicillin, also known as BRL-2333, is an antibiotic derived from penicillin G. It is similar to penicillin and ampicillin but can reach higher levels in the bloodstream. Amoxicillin was approved by the FDA in 1974.

Amoxicillin

is the brand name

image of different drug pills on a surface

Augmentin Es-600 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amoxicillin

1978

1067

Approved as Treatment by the FDA

Amoxicillin, also called Amoxicillin, is approved by the FDA for 2 uses including Duodenal Ulcer and Duodenal ulcer caused by helicobacter pylori .

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Effectiveness

How Augmentin Es-600 Affects Patients

Amoxicillin inhibits certain proteins related to the synthesis of the bacterial cell wall. This allows the body to destroy the bacteria. It is usually taken twice daily and has a wide range of safety, so mild overdoses are not too dangerous. Patients should be aware of the risk of anaphylaxis, infections caused by the bacteria _Clostridium difficile_, and the potential for bacteria to become resistant to the drug.

How Augmentin Es-600 works in the body

Amoxicillin works by blocking bacteria's ability to build and repair their cell wall. It does this by stopping penicillin-binding proteins, which are responsible for adding cross-links between D-alanine and D-aspartic acid molecules in the cell wall. Without these proteins, bacteria cannot create a strong enough cell wall to survive, so they die off.

When to interrupt dosage

The prescribed dosage of Augmentin Es-600 is contingent upon the specified condition, such as Lower Respiratory Tract Infection (LRTI), Duodenal Ulcer and Stomach Ulcer. The measure may vary as per the technique of administration (e.g. For suspension - Oral or Oral) mentioned in the following table.

Condition

Dosage

Administration

ear, nose, and throat infections

, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release - Oral, Tablet, extended release, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral

Gonorrhea

Sinusitis

Bronchitis

Otitis

ABDIC protocol

Duodenal Ulcer

Bacterial Infections

Urinary Tract Infection (UTI)

Peptic Ulcer With H. Pylori Infection

Community Acquired Pneumonia (CAP)

Urinary Tract Infections

Helicobacter Pylori Infection

Warnings

Augmentin Es-600 Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

Jaundice, Obstructive

Do Not Combine

Liver Dysfunction

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Amoxicillin may interact with Pulse Frequency

There are 20 known major drug interactions with Augmentin Es-600.

Common Augmentin Es-600 Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Amoxicillin.

Aclidinium

Minor

Amoxicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Amoxicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Amoxicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Allylestrenol

Minor

Amoxicillin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.

Augmentin Es-600 Toxicity & Overdose Risk

Patients who have overdosed on cephalexin may have bloody urine, a lack of urine production, abdominal pain, kidney failure, vomiting, diarrhea, rash, excessive energy, or drowsiness. Treatment for overdose may involve inducing vomiting or dialysis.

image of a doctor in a lab doing drug, clinical research

Augmentin Es-600 Novel Uses: Which Conditions Have a Clinical Trial Featuring Augmentin Es-600?

60 active clinical trials are undergoing to assess Augmentin Es-600's aptitude to combat Urinary Tract Infection, ENT Infections, and Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Bacterial Infections

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Bronchitis

2 Actively Recruiting

Not Applicable

ABDIC protocol

0 Actively Recruiting

ear, nose, and throat infections

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Sinusitis

2 Actively Recruiting

Not Applicable

Helicobacter Pylori Infection

2 Actively Recruiting

Not Applicable, Phase 4

Peptic Ulcer With H. Pylori Infection

0 Actively Recruiting

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Gonorrhea

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Otitis

3 Actively Recruiting

Not Applicable

Augmentin Es-600 Reviews: What are patients saying about Augmentin Es-600?

4.3

Patient Review

6/13/2017

Augmentin Es-600 for Skin Infection due to Staphylococcus Aureus Bacteria

Yes, the side effects can be unpleasant. But it's better than the alternative of dying.

4.3

Patient Review

1/1/2008

Augmentin Es-600 for Skin Infection

I started to experience itching after only six hours.

Patient Review

7/12/2012

Augmentin Es-600 for Middle Ear Infection

My 23 month old was vomiting by day three of taking this medication for an ear infection. I stopped giving it to him and called his doctor.

1.7

Patient Review

5/31/2010

Augmentin Es-600 for Middle Ear Infection

I would not recommend this medication to anyone, especially small children. It is incredibly hard to get your child to take it because of the taste, and it caused my son a lot of pain with severe diarrhea.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about augmentin es-600

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Augmentin and Augmentin ES?

"AUGMENTIN ES-600 contains more clavulanic acid than the other AUGMENTIN suspensions."

Answered by AI

Is Augmentin a strong antibiotic?

"Does Augmentin work better than amoxicillin? Augmentin can fight against a broader range of bacteria than amoxicillin alone. Therefore, Augmentin may be considered a stronger antibiotic than amoxicillin. The potency of the antibiotic depends on the infection and the type of bacteria causing the infection."

Answered by AI

What is Augmentin ES 600 used for?

"AUGMENTIN ES-600 is an antibiotic that contains two active ingredients. One is amoxicillin, a penicillin, and the other is clavulanic acid. AUGMENTIN ES-600 is used to treat children with infections caused by bacteria."

Answered by AI

How do you mix Augmentin ES 600?

"In a separate container, measure out the rest of the water. Add it to the mixture, screw the cap back on, and shake it vigorously. Each teaspoon (5 ml) of the mixture will contain 600 mg of amoxicillin as the trihydrate and 42.9 mg of clavulanic acid as the potassium salt. Make sure to shake the oral suspension well before each use."

Answered by AI

Clinical Trials for Augmentin Es-600

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

Drug

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD